全球生物模拟市场规模、份额、趋势和成长分析报告（2026-2034年）

预计生物模拟市场将从 2025 年的 47.7 亿美元成长到 2034 年的 203.1 亿美元，2026 年至 2034 年的复合年增长率为 17.47%。

受计算技术进步、研发投入增加以及製药、生物技术和学术领域应用日益广泛推动，全球生物模拟市场持续成长。计算能力的提升和生物模型的日益精细化提高了模拟精度，从而有助于药物发现和临床前开发阶段的早期决策。随着企业努力缩短产品上市时间并降低研发成本，生物模拟平台已从利基应用转变为研发流程的核心组成部分，从而促进了收入成长并扩大了市场渗透率。

全球生物模拟市场的主要驱动因素包括缩短研发週期的压力、监管机构对替代测试方法的鼓励，以及临床前研究中成本控制日益重要。机器学习、云端运算和大规模註释生物资料集等技术基础正在加速模型准确性和可及性的提升，并降低中小企业的准入门槛。软体供应商、受託研究机构(CRO) 和生命科学公司之间的合作，以及公共部门对数位生物学倡议的资助，进一步加速了生物模拟技术的应用。

随着系统生物学、人工智慧和多尺度建模的融合，全球生物模拟市场前景广阔，建构了一个更丰富、更可预测的平台，为精准医疗提供支援。检验研究、标准化工作和互通性是获得监管部门核准以及拓展应用场景（从药物发现到个人化医疗和安全性评估）的关键。能够提供整合化、用户友善套件并展现临床和监管价值的供应商，最有希望抓住不断增长的市场需求，尤其是在新兴市场。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球生物模拟市场：依产品划分

• 市场分析、洞察与预测
• 软体（分子建模、临床试验设计、PK/PD建模、PBPK建模、毒性预测等）
• 服务

第五章 全球生物模拟市场：依应用划分

• 市场分析、洞察与预测
• 药物发现与开发
• 疾病建模
• 其他领域（精准医疗、毒理学等）

第六章 全球生物模拟市场：依治疗领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 心血管疾病
• 感染疾病
• 神经系统疾病
• 其他的

第七章 全球生物模拟市场：依部署模式划分

• 市场分析、洞察与预测
• 基于云端的
• 现场
• 混合模式

第八章：全球生物模拟市场：依定价模式

• 市场分析、洞察与预测
• 基于许可的模式
• 订阅模式
• 基于服务的模式
• 计量收费模式

第九章 全球生物模拟市场：依最终用途划分

• 市场分析、洞察与预测
• 生命科学公司
• 学术研究机构
• 其他（例如，监管机构）

第十章 全球生物模拟市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十一章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十二章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Certara
  • USA. Dassault SystAfA¨Mes
  • Advanced Chemistry Development
  • Simulation Plus
  • Schrodinger Inc
  • Chemical Computing Group ULC
  • Physiomics Plc. Rosa & Co. LLC
  • BioSimulation Consulting Inc
  • Genedata AG
  • Instem Group Of Companies
  • PPD Inc
  • Yokogawa Insilico Biotechnology GmbH

The Biosimulation Market size is expected to reach USD 20.31 Billion in 2034 from USD 4.77 Billion (2025) growing at a CAGR of 17.47% during 2026-2034.

The Global Biosimulation Market has experienced steady expansion as advancements in computing, growing R&D investment, and broader adoption across pharmaceutical, biotech, and academic sectors converge. Increased computational power and more sophisticated biological models have improved simulation fidelity, enabling earlier decision-making in drug discovery and preclinical development. As companies seek to reduce time-to-market and development costs, biosimulation platforms have moved from niche use to core components of research pipelines, sustaining revenue growth and wider market penetration.

Key drivers for the Global Biosimulation Market include pressure to shorten development cycles, regulatory encouragement for alternative testing methods, and the rising emphasis on cost containment in preclinical research. Technological enablers such as machine learning, cloud computing, and larger annotated biological datasets accelerate model accuracy and accessibility, lowering barriers to entry for smaller organizations. Partnerships between software providers, contract research organizations, and life science firms, along with public funding for digital biology initiatives, further amplify adoption.

Future prospects for the Global Biosimulation Market are promising as systems biology, AI, and multi-scale modeling converge to create richer, more predictive platforms that support precision therapeutics. Validation studies, standardization efforts, and interoperability will be key to regulatory acceptance, broadening use cases from drug discovery to personalized medicine and safety assessment. Vendors that offer integrated, user-friendly suites and demonstrate clinical and regulatory value are best positioned to capture expanding demand, particularly in emerging markets.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Software (Molecular Modeling & Simulation Software, Clinical Trial Design Software, PK/PD Modeling and Simulation Software, bpk Modeling and Simulation Software, Toxicity Prediction Software, Other Software)
• Services

By Application

• Drug Discovery & Development
• Disease Modeling
• Other (Precision Medicine, Toxicology, etc.)

By Therapeutic Area

• Oncology
• Cardiovascular Disease
• Infectious Disease
• Neurological Disorders
• Others

By Deployment Model

• Cloud-based
• On-premise
• Hybrid Model

By Pricing Model

• License-based Model
• Subscription-based Model
• Service-based Model
• Pay Per Use Model

By End Use

• Life Sciences Companies
• Academic Research Institutions
• Others (Regulatory Authorities, etc.)

COMPANIES PROFILED

• Certara, USA Dassault Systmes, Advanced Chemistry Development, Simulation Plus, Schrodinger Inc, Chemical Computing Group ULC, Physiomics Plc Rosa Co LLC, BioSimulation Consulting Inc, Genedata AG, Instem Group of Companies, PPD Inc, Yokogawa Insilico Biotechnology GmbH
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMULATION MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Software (Molecular Modeling & Simulation Software, Clinical Trial Design Software, PK/PD Modeling and Simulation Software, bpk Modeling and Simulation Software, Toxicity Prediction Software, Other Software) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMULATION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Disease Modeling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other (Precision Medicine, Toxicology, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMULATION MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapeutic Area
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOSIMULATION MARKET: BY DEPLOYMENT MODEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Deployment Model
• 7.2. Cloud-based Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. On-premise Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Hybrid Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOSIMULATION MARKET: BY PRICING MODEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Pricing Model
• 8.2. License-based Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Subscription-based Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Service-based Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Pay Per Use Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BIOSIMULATION MARKET: BY END USE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End Use
• 9.2. Life Sciences Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Academic Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Others (Regulatory Authorities, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BIOSIMULATION MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Product
  • 10.2.2 By Application
  • 10.2.3 By Therapeutic Area
  • 10.2.4 By Deployment Model
  • 10.2.5 By Pricing Model
  • 10.2.6 By End Use
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Product
  • 10.3.2 By Application
  • 10.3.3 By Therapeutic Area
  • 10.3.4 By Deployment Model
  • 10.3.5 By Pricing Model
  • 10.3.6 By End Use
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Product
  • 10.4.2 By Application
  • 10.4.3 By Therapeutic Area
  • 10.4.4 By Deployment Model
  • 10.4.5 By Pricing Model
  • 10.4.6 By End Use
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Product
  • 10.5.2 By Application
  • 10.5.3 By Therapeutic Area
  • 10.5.4 By Deployment Model
  • 10.5.5 By Pricing Model
  • 10.5.6 By End Use
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Product
  • 10.6.2 By Application
  • 10.6.3 By Therapeutic Area
  • 10.6.4 By Deployment Model
  • 10.6.5 By Pricing Model
  • 10.6.6 By End Use
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL BIOSIMULATION INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Certara
  • 12.2.2 USA. Dassault SystAfA¨Mes
  • 12.2.3 Advanced Chemistry Development
  • 12.2.4 Simulation Plus
  • 12.2.5 Schrodinger Inc
  • 12.2.6 Chemical Computing Group ULC
  • 12.2.7 Physiomics Plc. Rosa & Co. LLC
  • 12.2.8 BioSimulation Consulting Inc
  • 12.2.9 Genedata AG
  • 12.2.10 Instem Group Of Companies
  • 12.2.11 PPD Inc
  • 12.2.12 Yokogawa Insilico Biotechnology GmbH